The Company's R&D strengths are in developing intellectual property in the area of non-infringing processes and resolving complex chemistry challenges. In the process, Aurobindo Pharma is developing new drug delivery systems, new dosage formulations, applying new technology for better processes.

The R&D Center, in Hyderabad covers over 13,000 sq.m, and provides a nurturing environment to a multi-disciplinary team of over 700 scientists striving for excellence.

The Centre meets cGLP requirements, and is focused on the areas of organic synthesis, analytical research, dosage form development, pharmacology, bio-equivalence studies and drug delivery systems.

The instrumentation and analytical knowledge base at the Centre facilitate,

  • Process development lifecycles of less than three months, even if it involves complex multi step synthesis with multiple chirality.
  • Complete impurity profiling in all products developed.
  • Development of analytical methods and specifications from raw materials, to non-compendia finished products.
  • In-house synthesis of reagents for analyzing organolithiums and noble metals.
  • Accelerated and real-time stability studies.

This reflects the Company's commitment towards developing innovative technologies and creating a knowledge base in chemical synthesis, high quality generic formulations and development of drug delivery systems.